| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.901231 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20250218135235 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 210629t20212021onc ob f00| 0 eng d |
|---|
| 020 | |a9780660394121 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-321/2021E-PDF |
|---|
| 245 | 00|aGuidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c2021. |
|---|
| 264 | 4|c©2021 |
|---|
| 300 | |a1 online resource (i, ii, 34 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19. |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"This guidance applies to sponsors of new COVID-19 drug submissions as well as sponsors seeking a notice of compliance (NOC) for COVID-19 drugs that received temporary authorization under the Interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19 (ISAD IO). It also applies to new COVID-19 drug establishment licences under the Food and Drug Regulations. This document will help manufacturers prepare a submission for a notice of compliance for a COVID-19 drug under the Regulations. It also outlines the process for meeting the post-market regulatory requirements"--page 1. |
|---|
| 650 | 0|aCOVID-19 Pandemic, 2020-2023|xHealth aspects|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19.|w(CaOODSP)9.901230 |
|---|
| 856 | 40|qPDF|s1.05 MB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-321-2021-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/food-drug-regulations-amendments-covid-19.html |
|---|
| 986 | |a210152 |
|---|